X

Trial Profile

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
Focus Therapeutic Use
Acronyms TARGET-IBD

Most Recent Events

19 Feb 2022 Results evaluating objective marker and TDM assessment in routine clinical practice prior to biologic therapeutic changes in adult IBD patients published in the BMC Gastroenterology
28 May 2021 New trial record
23 May 2021 Results (n=4229) presented at the Digestive Disease Week 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com